Physician profile
Sandra Diaz
NPI 1356703342
$9,317.79
in general payments reported to CMS, 2019-2025
27 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2021: $6,501 · 2022: $566 · 2023: $974 · 2024: $545 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.30 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,403.45 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $540.70 | 2021-2025 | |
| Hologic Sales and Service, LLC | $304.17 | 2021-2023 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Myovant Sciences INC. | $303.53 | 2021-2022 | |
| Astellas Pharma US INC | $257.85 | 2022-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $239.10 | 2023-2025 | Accrufer |
| Exeltis, USA INC. | $172.19 | 2021-2025 | Slynd |
| Abbvie INC. | $143.18 | 2021-2023 | Oriahnn, Lo Loestrin Fe, Orilissa |
| Amgen INC. | $137.83 | 2023-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $118.91 | 2021-2023 | |
| Coopersurgical, INC. | $98.04 | 2022-2024 | Paragard T 380a, Paragard T 380a, Wallach Cryosurgical Equipment |
| Biogen, INC. | $89.83 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $75.19 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $71.79 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $64.81 | 2023-2024 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $43.45 | 2022 | |
| Lupin INC. | $37.55 | 2021 | |
| Millicent US INC | $34.76 | 2025 | Intrarosa, Femring, Femlyv |
| Agile Therapeutics, INC. | $34.26 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $27.74 | 2021 | |
| Organon LLC | $23.23 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $19.08 | 2024 | Exparel |
| Vivus LLC | $17.34 | 2022 | |
| Smith+Nephew, INC. | $15.91 | 2024 | Pico, Pico 14 |
| Ethicon US, LLC | $15.54 | 2025 | Stratafix, Vistaseal, Ethicon |
| Daiichi Sankyo INC. | $14.82 | 2024 | Injectafer |
| Avion Pharmaceuticals | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.